Gyre Therapeutics (GYRE) Change in Receivables (2016 - 2026)
Gyre Therapeutics has reported Change in Receivables over the past 12 years, most recently at $4.8 million for Q4 2025.
- Quarterly Change in Receivables rose 321.03% to $4.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Dec 2025, up 11488.1% year-over-year, with the annual reading at $10.8 million for FY2025, 105.55% up from the prior year.
- Change in Receivables was $4.8 million for Q4 2025 at Gyre Therapeutics, up from $1.1 million in the prior quarter.
- Over five years, Change in Receivables peaked at $4.8 million in Q4 2025 and troughed at -$2.3 million in Q1 2021.
- The 5-year median for Change in Receivables is -$564000.0 (2022), against an average of $194888.9.
- Year-over-year, Change in Receivables tumbled 158.45% in 2022 and then skyrocketed 321.03% in 2025.
- A 5-year view of Change in Receivables shows it stood at $704000.0 in 2021, then plummeted by 180.11% to -$564000.0 in 2022, then crashed by 95.74% to -$1.1 million in 2023, then skyrocketed by 203.8% to $1.1 million in 2024, then surged by 321.03% to $4.8 million in 2025.
- Per Business Quant, the three most recent readings for GYRE's Change in Receivables are $4.8 million (Q4 2025), $1.1 million (Q4 2024), and -$1.1 million (Q4 2023).